Free Republic

Six months after the second Covaxin dose, a study using the vaccine as a booster dose has detected neutralising, T and B cell responses. This suggests good immune memory responses and long-term protection from severe disease, an official statement from Bharat Biotech said. The booster dose of whole-virus inactivated Covid-19 vaccine Covaxin (BBV152) may give long-term immunity against Sars-CoV-2 infection, its manufacturer Bharat Biotech announced on Saturday. A phase 2, double-blind, randomised controlled trial demonstrated long-term safety of Covaxin vaccine with no serious adverse events, the company said. Six months after the second Covaxin dose, a study using the vaccine...

Fauci: “I’m puzzled by that question,” he said about Covaxin. “We have more vaccines than we need right now. We just need the people to get vaccinated with the vaccines that we have. The mRNA vaccines are vaccines that are desired by everyone else in the world. So we have what we need; we need to use it.”

OVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. Immune memory against conserved nucleoprotein may provide an added advantage over spike-only responses Memory T and B cells persisted for at least 6 months post vaccination Data suggest COVAXIN™ (BBV152) may provide protection against current and future variants

India's indigenously-made 'Covaxin', one of the vaccines being used nationwide in the inoculation campaign against the COVID-19 pandemic, is on the UK's list of approved COVID-19 vaccines for international travellers from Monday. It will benefit more fully vaccinated Indians planning travel to the UK without the need for a pre-departure PCR test or self-isolation at the address declared on their compulsory Passenger Locator Forms. Like other fully vaccinated travellers, including those vaccinated with Covishield, they are required to pre-book a PCR or Lateral Flow Test on arrival in England, to be taken before the end of day 2. "From 4am...

LifeSiteNews published an article three weeks ago, on October 18, on Covaxin, a vaccine (a bona fide inactivated virus vaccine, not an mRNA neologism) developed by Bharat Biotech in India. It could potentially prove a breakthrough in many Catholics’ long wait for a vaccine that would satisfy the dual concerns of ethical unimpeachability and medical safety. This is because, in addition to being a standard, true-blue vaccine (cultured in cell lines derived from monkey tissue), Covaxin also has—as yet—no known connection to cell lines derived from aborted fetal tissue. The World Health Organization, of course, exhibited a slow pace in...

The World Health Organization (WHO) has granted approval for emergency use to India's government-backed Covid-19 vaccine, Covaxin. The vaccine was approved in India in January while the third phase of clinical trials was still under way, sparking some concern and criticism. Bharat Biotech, which makes the vaccine, has since published data suggesting 78% efficacy. The WHO said in a tweet it believed the benefits far outweighed the risks. Some experts had pointed to a fast-track approval and incomplete data, but the firm's chairman, Dr Krishna Ella, said the vaccine was "200% safe". The WHO's expert panel, which authorises emergency approvals,...

Novavax may jump ahead of AstraZeneca as the drugmaker most likely to get its COVID-19 vaccine approved next by the FDA, Politico reported April 27. Below are seven key details about Novavax and its COVID-19 vaccine: 1. Novavax, founded in 1987 and based in Gaithersburg, Md., has never brought a product to market. 2. The drugmaker's COVID-19 vaccine candidate is a subunit vaccine made of proteins resembling those on the surface of the novel coronavirus, which are meant to generate an immune response to the virus. It does not require ultracold storage, as do the COVID-19 vaccines produced by Pfizer...

India’s ambitious but troubled campaign to inoculate its vast population against Covid-19 — and, in the process, to burnish its reputation as a manufacturer and innovator — received a major lift after initial trial results showed a homegrown vaccine was safe and effective. Bharat Biotech, the Indian drug company that developed the shots, said late Wednesday that early findings from clinical trials involving nearly 26,000 subjects showed that the vaccine, Covaxin, had an initial efficacy rate of 81 percent. The results have yet to be peer reviewed, the company said, and it was unclear how effective Covaxin would prove to...

Hyderabad: COVAXIN, India's first vaccine against the novel coronavirus, developed by Bharat Biotech, Hyderbad-based biotechnology firm in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), gets nod from the Drug Controller General of India (DCGI) to conduct Phase I and 2 human trials. According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020. A note issued by the company says, "The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine was developed and...